Last reviewed · How we verify

CD11301 0.06% — Competitive Intelligence Brief

CD11301 0.06% (CD11301 0.06%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: retinoid. Area: Dermatology.

phase 2 retinoid retinoic acid receptors Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

CD11301 0.06% (CD11301 0.06%) — Galderma R&D. CD11301 is a topical retinoid that modulates the retinoic acid pathway to treat acne.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
CD11301 0.06% TARGET CD11301 0.06% Galderma R&D phase 2 retinoid retinoic acid receptors
Tretinoin gel Tretinoin gel Bausch Health Americas, Inc. marketed Retinoid Retinoic acid receptors (RAR-alpha, RAR-beta, RAR-gamma)
tretinoin 0.025% cream tretinoin 0.025% cream Wake Forest University marketed Retinoid Retinoic acid receptors (RAR-alpha, RAR-beta, RAR-gamma)
Tretinoin 0.05% Tretinoin 0.05% Pontificia Universidad Catolica de Chile marketed Retinoid Retinoic acid receptors (RAR-α, RAR-β, RAR-γ)
Tretinoin cream 0.05 Tretinoin cream 0.05 Massachusetts General Hospital marketed Retinoid Retinoic acid receptors (RAR-alpha, RAR-beta, RAR-gamma)
Tretinoin Gel (tretinoin) Tretinoin Gel (tretinoin) Stiefel, a GSK Company marketed Retinoid Retinoic acid receptors (RAR-α, RAR-β, RAR-γ)
BENZOYL PEROXIDE/ ADAPALENE BENZOYL PEROXIDE/ ADAPALENE Stiefel, a GSK Company marketed Retinoid + peroxide combination Retinoic acid receptors (adapalene); bacterial cell oxidative stress (benzoyl peroxide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (retinoid class)

  1. Galderma R&D · 2 drugs in this class
  2. Encube Ethicals Pvt. Ltd. · 1 drug in this class
  3. Fougera Pharmaceuticals Inc. · 1 drug in this class
  4. Kowa Company, Ltd. · 1 drug in this class
  5. South Plains Oncology Consortium · 1 drug in this class
  6. Stiefel, a GSK Company · 1 drug in this class
  7. Actavis Inc. · 1 drug in this class
  8. Teva Pharmaceuticals USA · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CD11301 0.06% — Competitive Intelligence Brief. https://druglandscape.com/ci/cd11301-0-06. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: